IL241009A0 - Anti-egfr antibody and drug conjugate formulations - Google Patents

Anti-egfr antibody and drug conjugate formulations

Info

Publication number
IL241009A0
IL241009A0 IL241009A IL24100915A IL241009A0 IL 241009 A0 IL241009 A0 IL 241009A0 IL 241009 A IL241009 A IL 241009A IL 24100915 A IL24100915 A IL 24100915A IL 241009 A0 IL241009 A0 IL 241009A0
Authority
IL
Israel
Prior art keywords
drug conjugate
antibody drug
egfr antibody
conjugate formulations
formulations
Prior art date
Application number
IL241009A
Other languages
English (en)
Hebrew (he)
Original Assignee
Abbvie Inc
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Abbvie Deutschland filed Critical Abbvie Inc
Publication of IL241009A0 publication Critical patent/IL241009A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL241009A 2013-03-15 2015-09-01 Anti-egfr antibody and drug conjugate formulations IL241009A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790490P 2013-03-15 2013-03-15
PCT/US2014/027868 WO2014143765A1 (en) 2013-03-15 2014-03-14 Anti-egfr antibody drug conjugate formulations

Publications (1)

Publication Number Publication Date
IL241009A0 true IL241009A0 (en) 2015-11-30

Family

ID=50680154

Family Applications (2)

Application Number Title Priority Date Filing Date
IL241009A IL241009A0 (en) 2013-03-15 2015-09-01 Anti-egfr antibody and drug conjugate formulations
IL274881A IL274881A (en) 2013-03-15 2020-05-24 Anti-EGFR antibody and drug conjugate formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL274881A IL274881A (en) 2013-03-15 2020-05-24 Anti-EGFR antibody and drug conjugate formulations

Country Status (28)

Country Link
US (2) US20140286969A1 (enExample)
EP (2) EP3517132A1 (enExample)
JP (4) JP6382935B2 (enExample)
KR (4) KR102305226B1 (enExample)
CN (2) CN105163763B (enExample)
AU (4) AU2014228172B2 (enExample)
BR (1) BR112015023391A8 (enExample)
CA (1) CA2906130A1 (enExample)
CY (1) CY1121949T1 (enExample)
DK (1) DK2968588T3 (enExample)
ES (1) ES2727134T3 (enExample)
HK (1) HK1219044A1 (enExample)
HR (1) HRP20190672T1 (enExample)
HU (1) HUE044071T2 (enExample)
IL (2) IL241009A0 (enExample)
LT (1) LT2968588T (enExample)
ME (1) ME03457B (enExample)
MX (2) MX2015012549A (enExample)
NZ (1) NZ630826A (enExample)
PL (1) PL2968588T3 (enExample)
PT (1) PT2968588T (enExample)
RS (1) RS58666B1 (enExample)
RU (2) RU2015144287A (enExample)
SG (2) SG10201707633VA (enExample)
SI (1) SI2968588T1 (enExample)
TR (1) TR201905313T4 (enExample)
TW (3) TWI689313B (enExample)
WO (1) WO2014143765A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707302B2 (en) * 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10570211B2 (en) 2011-01-24 2020-02-25 Gilead Sciences, Inc. Antibodies selective for cells presenting EGFR at high density
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3223857A4 (en) * 2014-10-31 2018-06-27 Formation Biologics Inc. Egfr antibody-based combination therapy
US10195175B2 (en) * 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017051249A1 (en) 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-cd19 antibody drug conjugates
WO2017051254A1 (en) * 2015-09-25 2017-03-30 Legochem Biosciences, Inc. Compositions and methods related to anti-egfr antibody drug conjugates
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ， インク． ペプチド基を含む複合体及びそれに関連する方法
RS61659B1 (sr) * 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
CN109562190A (zh) * 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
EP3808748B1 (en) * 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
AU2018280485A1 (en) * 2017-06-06 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising c-Met antibody-drug conjugate and use thereof
KR20250004902A (ko) * 2017-08-23 2025-01-08 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
EP3677589B1 (en) 2017-08-31 2025-11-26 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
EP3852617B1 (en) * 2018-09-20 2025-09-10 SFJ Pharma X, Inc. Use of antibody fragments for reversing ticagrelor activity
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
JP7570341B2 (ja) * 2019-03-04 2024-10-21 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
SG11202104269PA (en) * 2019-03-26 2021-05-28 Remegen Co Ltd Anti-her2 antibody drug conjugate pharmaceutical preparation
WO2020233534A1 (zh) * 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
KR102793948B1 (ko) * 2019-08-07 2025-04-11 맙플렉스 인터내셔널 컴퍼니 리미티드 항체-약물 접합체 및 이의 용도
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
CN112516090B (zh) * 2019-09-18 2023-06-20 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途
MX2022012711A (es) * 2020-04-10 2023-01-16 Lantern Pharma Inc Hidroxiureametil-acilfulveno para tratar el cáncer de cerebro o el cáncer del snc.
US20240000961A1 (en) * 2020-11-11 2024-01-04 The Catholic University Of Korea Industry-Academic Cooperation Foundation Antibody-based conjugate for enhancing therapeutic effect of targeted therapeutic agent
KR102683876B1 (ko) * 2020-11-11 2024-07-11 가톨릭대학교 산학협력단 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트
CN116761632A (zh) * 2020-11-11 2023-09-15 加图立大学校产学协力团 用于增强靶向治疗剂的治疗效果的基于抗体的缀合物
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN115300623B (zh) * 2021-05-08 2024-06-21 盛禾(中国)生物制药有限公司 抗egfr融合蛋白或其抗原结合片段的组合物及其用途
EP4337676A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs
CN115721732B (zh) * 2021-08-27 2025-03-07 上海复旦张江生物医药股份有限公司 抗体偶联药物的药物组合物、制剂及其制备方法、用途
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン， インコーポレイテッド 抗ｉｇｆ－１ｒ抗体組成物
JP2025522442A (ja) * 2022-06-15 2025-07-15 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 抗体薬物複合体を含有する医薬組成物およびその使用
EP4353220A1 (en) * 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
EP4653017A1 (en) 2023-01-18 2025-11-26 Tyligand Bioscience (Shanghai) Limited Antibody-drug conjugate and use thereof
WO2025113442A1 (zh) * 2023-11-29 2025-06-05 四川科伦博泰生物医药股份有限公司 抗体制剂
WO2025148868A1 (zh) 2024-01-08 2025-07-17 泰励生物科技（上海）有限公司 一种抗体偶联药物及其用途

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
ATE207366T1 (de) * 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US20050023292A1 (en) * 2003-02-14 2005-02-03 Rubbermaid Commercial Products Llc Liquid dispenser
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
CA2559870A1 (en) 2004-04-07 2005-10-27 Genetech,Inc. Mass spectrometry of antibody conjugates
TR201808537T4 (tr) * 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1909846B1 (en) 2005-08-05 2018-12-26 Syntarga B.V. Triazole-containing releasable linkers, conjugates comprising the same and processes for their preparation
MX2012002651A (es) * 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
KR20130031247A (ko) * 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
WO2011140254A1 (en) * 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TW201519904A (zh) * 2013-03-15 2015-06-01 Abbvie Inc 抗體藥物結合物（ａｄｃ）之純化
SI3108009T1 (sl) * 2014-02-18 2021-09-30 Illumina, Inc. Postopki in sestavki za profiliranje DNK

Also Published As

Publication number Publication date
SG10201707633VA (en) 2017-11-29
CA2906130A1 (en) 2014-09-18
AU2020277164A1 (en) 2020-12-24
ME03457B (me) 2020-01-20
RU2020125266A (ru) 2020-09-24
US20200282072A1 (en) 2020-09-10
KR20220139443A (ko) 2022-10-14
LT2968588T (lt) 2019-05-10
CN110433139A (zh) 2019-11-12
AU2023200432A1 (en) 2023-03-02
HK1217644A1 (en) 2017-01-20
NZ732015A (en) 2022-01-28
EP2968588B1 (en) 2019-01-09
JP2016515511A (ja) 2016-05-30
JP2018184468A (ja) 2018-11-22
HRP20190672T1 (hr) 2019-08-23
CY1121949T1 (el) 2020-10-14
AU2018267662A1 (en) 2018-12-13
KR20220041957A (ko) 2022-04-01
MX2020000333A (es) 2020-07-13
CN105163763B (zh) 2019-07-02
BR112015023391A8 (pt) 2018-01-30
KR20150131366A (ko) 2015-11-24
TR201905313T4 (tr) 2019-05-21
TW201945032A (zh) 2019-12-01
EP2968588A1 (en) 2016-01-20
KR20210118238A (ko) 2021-09-29
HK1219044A1 (zh) 2017-03-24
RS58666B1 (sr) 2019-06-28
AU2014228172B2 (en) 2018-12-06
BR112015023391A2 (pt) 2017-11-28
TW202146054A (zh) 2021-12-16
IL274881A (en) 2020-07-30
SI2968588T1 (sl) 2019-05-31
JP6382935B2 (ja) 2018-08-29
EP3517132A1 (en) 2019-07-31
PT2968588T (pt) 2019-05-08
KR102305226B1 (ko) 2021-09-29
SG11201507430RA (en) 2015-10-29
MX2015012549A (es) 2016-06-21
TW201519903A (zh) 2015-06-01
US20140286969A1 (en) 2014-09-25
NZ630826A (en) 2017-06-30
HUE044071T2 (hu) 2019-09-30
WO2014143765A1 (en) 2014-09-18
RU2015144287A (ru) 2017-04-24
CN105163763A (zh) 2015-12-16
PL2968588T3 (pl) 2019-08-30
ES2727134T3 (es) 2019-10-14
WO2014143765A8 (en) 2015-09-11
RU2015144287A3 (enExample) 2018-03-19
DK2968588T3 (en) 2019-04-23
JP2020143152A (ja) 2020-09-10
TWI689313B (zh) 2020-04-01
JP2022126754A (ja) 2022-08-30
AU2014228172A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
IL274881A (en) Anti-EGFR antibody and drug conjugate formulations
IL291073A (en) Drug conjugates of anti-egfr antibodies
IL275103A (en) Antibody Formulations
ZA201505656B (en) Antibody drug conjugates
EP2982681B8 (en) Wt1-antigen peptide conjugate vaccine
IL244712B (en) Anti- pdl1 antibody compositions
ZA201508487B (en) Antibody drug conjugates
EP2968600A4 (en) Antibody drug conjugates
IL252441A0 (en) Conjugation of antibody to c-met and drug
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
ZA201600027B (en) Pharmaceutical preparation
ZA201506465B (en) Pharmaceutical preparation